Aurealis Therapeutics

Biotechnology Research • Kuopio, Northern Savonia, Finland • 11-20 Employees

Company overview

Headquarters	Microkatu 1, Kuopio, 70210, FI
Website	aurealistherapeutics.com
NAICS	541714
SIC	283
Keywords	Oncology, Inflammation, Chronic Wounds, Cell And Gene Therapy, Oncolytic Bacteria, Recombinant Live Biotherapeutic, Advanced Therapy Medicinal Product
Founded	2015
Employees	11-20
Socials

Key Contacts at Aurealis Therapeutics

Jere Kurkipuro

Director Of Preclinical And Pharmacology

Hanna-Riikka Kärkkäinen

Director Of Quality And Regulatory Affairs

Mirka Sanio

Clinical Operations Director

Aurealis Therapeutics Email Formats

Aurealis Therapeutics uses 4 email formats. The most common is {first initial} (e.g., j@aurealistherapeutics.com), used 40% of the time.

Format	Example	Percentage
{first initial}	j@aurealistherapeutics.com	40%
{first name}	john@aurealistherapeutics.com	30%
{first name}.{last name}	john.doe@aurealistherapeutics.com	20%
{first initial}.{last name}	j.doe@aurealistherapeutics.com	10%

About Aurealis Therapeutics

Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation. After successfully completing our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead clinical product AUP-16, our DFU Phase 2 study is ongoing in Italy, Germany and Poland. Venous Ulcers and other ulcers will follow. In Oncology, we are building on impressive pre-clinical data with Oncolytic Bacteria lead candidate AUP-55, which shows increased survival in Ovarian Cancer and peritoneal carcinomatosis. Our pipeline also includes Inflammation, at discovery stage.

Aurealis Therapeutics revenue & valuation

Annual revenue	$3,000,000
Revenue per employee	$167,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$9,600,000
Total funding	$28,000,000

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Director

C-Suite

Entry

Employees by Department

Aurealis Therapeutics has 5 employees across 5 departments.

Departments

Number of employees

Funding Data

Explore Aurealis Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2023-04-30	4	$10,000,000
2024-12-13	15	$9,000,000
2024-12-13	1	$9,000,000

Funding Insights

$28,000,000

Total funding amount

$9,000,000

Most recent funding amount

Number of funding rounds

Aurealis Therapeutics Tech Stack

Discover the technologies and tools that power Aurealis Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Autoptimize

Performance

jQuery UI

JavaScript libraries

Google Maps

Maps

Hello Elementor

WordPress themes

Elementor

Page builders

Microsoft 365

jQuery Migrate

JavaScript libraries

jQuery

JavaScript libraries

HubSpot Analytics

Analytics

PHP

Programming languages

WordPress

Blogs

Google Analytics

Analytics

Frequently asked questions

Aurealis Therapeutics is located in Kuopio, Northern Savonia, FI.

Aurealis Therapeutics was founded in 2015, making it 11 years old. The company has established itself as a significant player in its industry over this time.

Aurealis Therapeutics has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

Aurealis Therapeutics has raised a total of $28,000,000 across 3 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at Aurealis Therapeutics

Jere Kurkipuro

Director Of Preclinical And Pharmacology

Hanna-Riikka Kärkkäinen

Director Of Quality And Regulatory Affairs

Mirka Sanio

Clinical Operations Director

4.8

40,000 users